Use of MDL-100,907 for treatment of allergic and eosinophil mediated diseases

A method of reducing or decreasing progression, severity, frequency, duration or probability of one or more symptoms associated with asthma, comprising administering to a subject an amount of 5-HT2A receptor antagonist sufficient to reduce or decrease progression, severity, frequency, duration or probability of the symptom associated with asthma.

A method of treating a subject having or at risk of having a condition associated with undesirable or abnormal eosinophil migration, chemotaxis or generation, comprising administering to a subject an amount of 5-HT2A receptor antagonist sufficient to reduce or decrease undesirable or abnormal eosinophil migration, chemotaxis or generation thereby treating the subject.

A method of reducing or decreasing the probability, severity, frequency, duration or preventing a subject from having an acute asthmatic episode, comprising administering to a subject that has previously experienced an asthmatic episode or has been diagnosed as having asthma with an amount of 5-HT2A receptor antagonist sufficient to reduce or decrease the probability, severity, frequency, duration or prevent an acute asthmatic episode.

A method of increasing airway-dilation, comprising administering to a subject in need of increasing airway-dilation an amount of 5-HT2A receptor antagonist sufficient to increase airway-dilation in the subject.

A method of reducing the probability, severity, frequency, duration or preventing airway-constriction, comprising administering to a subject in need of reducing the probability, severity, frequency, duration or preventing airway-constriction an amount of 5-HT2A receptor antagonist sufficient to reduce or decrease the probability, severity, frequency, duration or prevent airway-constriction in the subject.

64-89. (canceled)